Physician profile
Anna Shostak
NPI 1447275730
$15,813.45
in general payments reported to CMS, 2019-2025
26 companies · $2,400 in 2025
The $2,400 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,269 · 2020: $2,013 · 2021: $2,420 · 2022: $1,906 · 2023: $2,019 · 2024: $1,787 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,206.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,955.88 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $2,088.59 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,427.36 | 2019-2025 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $1,358.64 | 2019-2024 | Austedo, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $1,136.67 | 2019-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $846.28 | 2020-2025 | Jardiance |
| Avanir Pharmaceuticals, INC. | $703.08 | 2019-2022 | |
| Allergan, INC. | $639.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $622.74 | 2019-2024 | Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $615.68 | 2020-2024 | Airsupra |
| Amgen INC. | $613.18 | 2020-2022 | |
| Axsome Therapeutics, INC. | $557.39 | 2023-2025 | Auvelity, Symbravo |
| Sunovion Pharmaceuticals INC. | $396.99 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $284.57 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $188.14 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $144.45 | 2024 | Spin Vision Video Processor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.33 | 2022 | |
| Lundbeck LLC | $134.45 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Medtronic, INC. | $127.23 | 2022 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Lilly USA, LLC | $125.00 | 2025 | Mounjaro |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Pfizer INC. | $124.96 | 2020 | |
| Novo Nordisk INC | $120.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.36 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $101.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Shostak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.